JP2017095440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017095440A5 JP2017095440A5 JP2016181594A JP2016181594A JP2017095440A5 JP 2017095440 A5 JP2017095440 A5 JP 2017095440A5 JP 2016181594 A JP2016181594 A JP 2016181594A JP 2016181594 A JP2016181594 A JP 2016181594A JP 2017095440 A5 JP2017095440 A5 JP 2017095440A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- excipient
- concentration
- formulation
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562222067P | 2015-09-22 | 2015-09-22 | |
| US62/222067 | 2015-09-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017095440A JP2017095440A (ja) | 2017-06-01 |
| JP2017095440A5 true JP2017095440A5 (https=) | 2019-10-24 |
| JP6925111B2 JP6925111B2 (ja) | 2021-08-25 |
Family
ID=57045234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016181594A Expired - Fee Related JP6925111B2 (ja) | 2015-09-22 | 2016-09-16 | 治療用タンパク質製剤を調製する方法、およびそのような方法により生成される抗体製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230134160A1 (https=) |
| EP (1) | EP3352790A1 (https=) |
| JP (1) | JP6925111B2 (https=) |
| KR (2) | KR20180037056A (https=) |
| CN (1) | CN108025072A (https=) |
| AU (1) | AU2016329034B2 (https=) |
| CA (1) | CA2999118C (https=) |
| HK (1) | HK1255006A1 (https=) |
| IL (1) | IL258311B (https=) |
| MX (1) | MX2018003298A (https=) |
| WO (1) | WO2017051273A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3024618A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| CN118512588A (zh) | 2017-10-26 | 2024-08-20 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
| CN119488586A (zh) * | 2018-03-26 | 2025-02-21 | 勃林格殷格翰动物保健美国有限公司 | 制备免疫原性组合物的方法 |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| US12312394B2 (en) | 2018-06-28 | 2025-05-27 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5 antibodies |
| US12103949B2 (en) * | 2018-08-14 | 2024-10-01 | Bristol-Myers Squibb Company | Protein recovery |
| CN111110841A (zh) * | 2018-10-31 | 2020-05-08 | 上海君实生物医药科技股份有限公司 | 含有抗pcsk9抗体的稳定制剂 |
| EP4653041A3 (en) | 2019-01-24 | 2026-03-04 | Magenta Medical Ltd. | Ventricular assist device |
| TWI871300B (zh) * | 2019-01-28 | 2025-02-01 | 美商安進公司 | 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| EP4111208A4 (en) * | 2020-02-24 | 2024-04-10 | Indian Institute of Technology, Delhi | REAL-TIME MONITORING SYSTEM OF PROTEIN AND EXCELLENT SUBSTANCES |
| CN111944046B (zh) * | 2020-08-28 | 2021-04-09 | 江苏荃信生物医药有限公司 | 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法 |
| WO2022041390A1 (zh) * | 2020-08-28 | 2022-03-03 | 江苏荃信生物医药股份有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法 |
| WO2022142053A1 (en) * | 2020-12-30 | 2022-07-07 | I-Mab Biopharma Co., Ltd | Formulations of anti-cd73 antibodies |
| CN114014929B (zh) * | 2021-11-04 | 2022-07-19 | 江苏荃信生物医药股份有限公司 | 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法 |
| EP4429754B1 (en) | 2022-09-14 | 2025-02-12 | Magenta Medical Ltd. | Pump-head portion of ventricular assist device |
| TW202432179A (zh) * | 2023-02-08 | 2024-08-16 | 瑞士商百濟神州瑞士有限責任公司 | 用於高度濃縮的ｐｄ１抗體溶液的超濾／滲濾方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9415102B2 (en) * | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| ES2569409T3 (es) * | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| CL2007003583A1 (es) * | 2006-12-11 | 2008-07-18 | Hoffmann La Roche | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| WO2010042705A1 (en) * | 2008-10-09 | 2010-04-15 | Medimmune, Llc | Antibody formulation |
| AR080291A1 (es) * | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| CA2790786C (en) * | 2010-02-24 | 2019-09-24 | Zymenex A/S | Process for production and purification of recombinant lysosomal alpha-mannosidase |
| WO2012168491A1 (en) * | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| EP2583980A1 (en) * | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| BR112014028129A2 (pt) * | 2012-05-14 | 2017-06-27 | Novo Nordisk As | soluções de proteína estabilizadas |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| EP2727602A1 (en) * | 2012-10-31 | 2014-05-07 | Takeda GmbH | Method for preparation of a high concentration liquid formulation of an antibody |
-
2016
- 2016-09-08 MX MX2018003298A patent/MX2018003298A/es unknown
- 2016-09-08 US US15/761,777 patent/US20230134160A1/en active Pending
- 2016-09-08 EP EP16774987.8A patent/EP3352790A1/en active Pending
- 2016-09-08 CN CN201680054397.XA patent/CN108025072A/zh active Pending
- 2016-09-08 WO PCT/IB2016/055355 patent/WO2017051273A1/en not_active Ceased
- 2016-09-08 CA CA2999118A patent/CA2999118C/en active Active
- 2016-09-08 KR KR1020187007855A patent/KR20180037056A/ko not_active Ceased
- 2016-09-08 HK HK18114122.2A patent/HK1255006A1/zh unknown
- 2016-09-08 AU AU2016329034A patent/AU2016329034B2/en not_active Ceased
- 2016-09-08 KR KR1020207008879A patent/KR20200035496A/ko not_active Ceased
- 2016-09-16 JP JP2016181594A patent/JP6925111B2/ja not_active Expired - Fee Related
-
2018
- 2018-03-22 IL IL258311A patent/IL258311B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017095440A5 (https=) | ||
| MX2018003298A (es) | Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo. | |
| AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
| Saso et al. | Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality? | |
| JP2012097086A5 (https=) | ||
| JP2016520075A5 (https=) | ||
| HRP20210743T1 (hr) | Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline | |
| UA102166C2 (ru) | Композиция для подкожного введения, которая содержит антитело к her2 | |
| JP2013531679A5 (https=) | ||
| RU2011127913A (ru) | Составы, содержащие антитела | |
| JP2014520852A5 (https=) | ||
| JP2016534052A5 (https=) | ||
| JP2013511481A5 (https=) | ||
| AR097840A1 (es) | Una formulación de un conjugado de la hormona de crecimiento humana de la actividad prolongada, procedimiento, kit | |
| EA201492014A1 (ru) | Получение ротавирус-подобных частиц в растениях | |
| WO2018097603A3 (ko) | 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법 | |
| HRP20201242T1 (hr) | Tekući farmaceutski pripravak | |
| JP2013530719A5 (https=) | ||
| JP2017525679A5 (https=) | ||
| PE20210629A1 (es) | Anticuerpos anti-klk5 y metodos de uso | |
| JP2014519817A5 (https=) | ||
| JP2017525704A5 (https=) | ||
| JP2017525680A5 (https=) | ||
| McCool et al. | Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope | |
| EA202092926A2 (ru) | Лиофилизированные составы, содержащие фактор ix |